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Abstract
Introduction: This study examines the expression of IL-17A-secreting cells within the inflamed synovium and the
relationship to in vivo joint hypoxia measurements.
Methods: IL-17A expression was quantified in synovial tissue (ST), serum and synovial fluid (SF) by immunohistochemistry
and MSD-plex assays. IL-6 SF and serum levels were measured by MSD-plex assays. Dual immunofluorescence for IL-17A was
quantified in ST CD15+ cells (neutrophils), Tryptase+ (mast cells) and CD4+ (T cells). Synovial tissue oxygen (tpO2) levels
were measured under direct visualisation at arthroscopy. Synovial infiltration was assessed using immunohistochemistry for
cell specific markers. Peripheral blood mononuclear and polymorphonuclear cells were isolated and exposed to normoxic or
3% hypoxic conditions. IL-17A and IL-6 were quantified as above in culture supernatants.
Results: IL-17A expression was localised to mononuclear and polymorphonuclear (PMN) cells in inflamed ST. Dual
immunoflourescent staining co-localised IL-17A expression with CD15+ neutrophils Tryptase+ mast cells and CD4+T cells. %
IL-17A positivity was highest on CD15+ neutrophils, followed by mast cells and then CD4+T-cells. The number of IL-17A-
secreting PMN cells significantly correlated with sublining CD68 expression (r=0.618, p,0.01). IL-17A SF levels correlated
with IL-6 SF levels (r=0.675, p,0.01). Patients categorized according to tp02, or .20mmHg, showed those with low
tp02,20mmHg had significantly higher IL-17A+ mononuclear cells with no difference observed for PMNs. Exposure of
mononuclear and polymorphonuclear cells to 3% hypoxia, significantly induced IL-6 in mononuclear cells, but had no effect
on IL-17A expression in mononuclear and polymorphonuclear cells.
Conclusion: This study demonstrates IL-17A expression is localised to several immune cell subtypes within the inflamed
synovial tissue, further supporting the concept that IL-17A is a key mediator in inflammatory arthritis. The association of
hypoxia with Il-17A expression appears to be indirect, probably through hypoxia-induced pro-inflammatory pathways and
leukocyte influx within the joint microenvironment.
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Introduction
Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) are the
most common forms of the inflammatory rheumatic diseases
characterised by synovitis and progressive destruction of articular
cartilage and bone [1,2]. Angiogenesis is a primary crucial step in
disease pathogenesis which facilitates the recruitment and migra-
tion of inflammatory cell types into the inflamed joint cavity [3].
Subsequently, the synovial lining layer thickens and the sublining
is infiltrated with T cells, B cells, mast cells, neutrophils, monocytes
and macrophages which secrete a wide range of mediators which
further exacerbate the inflammatory response [4,5], however little
is known about the role of mast cells in driving the inflammatory
response.
Mast cells have been implicated in IgE-mediated immune
responses in the context of allergic disease and defence against
helminths [6,7]. Recent studies in the K/BxN mouse model
however, have firmly established mast cells as having a critical role
in the pathogenesis of inflammatory arthritis [8,9]. These findings
have renewed interest in previous histological studies demonstrat-
ing a marked increase in mast cell expression in the human RA
synovial sublining, in particular at sites of cartilage erosion, and
their relationship to increased joint inflammation [7,10]. Further-
more, mast cell derived mediators such as tryptase have been
implicated in the activation of synovial fibroblasts and proteogly-
can depletion [11].
Targeted biologic agents in particular TNF inhibitors (TNFi)
have advanced the treatment of both RA and PsA, although some
patients do not respond highlighting the need for alternative
therapies. The pro-inflammatory cytokine IL-17A is one such
potential target. IL-17A is the first identified member of the IL-17
family (A–F), it is most closely related to IL-17F with 50%
sequence homology [12]. IL-17A has been localized to T-cell rich
areas in the RA synovium and overexpression of IL-17A has been
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patients compared to OA and healthy control subjects [13,14,
15,16]. Furthermore, expression of IL-17A correlates with disease
activity and clinical response that can be modulated by both
DMARD and TNFi therapy [13,17]. In humans Th17 cells are a
key source of IL-17A when activated by a number of key cytokines
required for their development including TGF-b, IL-6, IL-21, IL-1
and IL-23 [18]. In addition to Th17 cells, cdT, NK, NKT and
innate immune cells such as mast cells and neutrophils have been
identified as sources of IL-17A in murine studies [19] and more
recently in humans [20]. IL-17A, alone and in combination with
other proinflammatory cytokines, drives ECM remodelling and
cartilage destruction through the induction of MMPs [13].
Hypoxia has been implicated in RA pathogenesis, previous
studies have demonstrated that the level of oxygen in SF from
patients with RA is reduced compared to healthy controls. Low
oxygen levels have been reported in tenosynovium from RA
patients with tendon rupture [21]. More recently we have demon-
strated profound hypoxia in inflamed ST using an oxygen sensing
probe in vivo, levels of which were inversely associated with
synovial inflammation and blood vessel morphology [22,23]
Several studies using synovial cells, have shown that hypoxia
may induce key angiogenic growth factors (VEGF and Angio-
poietins), chemokines (MCP-1, IL-8, MIP-3a) and MMPs 21, 23
and 29 while downregulating IL-10 [23,24]. Furthermore
sustained hypoxia activates NF-kB dependent gene expression,
which is a key regulator of inflammation genes [25]. Together this
data highlights the ability of hypoxia to regulate diverse signalling
pathways that are involved in the pro-inflammatory response.
In this study we demonstrate that IL-17A is expressed by
important immune cells including mast cells within the inflamed
synovium. Furthermore, we demonstrate a relationship between in
vivo measures of hypoxia and IL-17A producing cells in the inflamed
joint; however it is unclear whether this effect is direct or indirect.
Materials and Methods
Patient recruitment
Patients with active inflammatory arthritis, RA and PsA, were
recruited from outpatient clinics at Department of Rheumatology,
St. Vincent’s University Hospital (SVUH). All patients fulfilled
diagnostic criteria for RA or PsA [26,27]. This study was approved
by St. Vincent’s University Hospital institutional ethics committee,
and all patients gave their fully informed written consent prior to
inclusion in the study. All patients had active disease despite being
on disease modifying anti-rheumatic drugs (DMARDs), had at
least one inflamed knee joint and were commencing on biologic
therapy. Clinical and laboratory assessment included tender
and swollen joint count, rheumatoid factor, anti-CCP antibody
(ACPA), erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and global health visual analogue scale (VAS) obtained on
the same day as the arthroscopy.
Arthroscopy, oxygen measurements and sample
collection
Arthroscopy of the inflamed knee was performed under local
anaesthetic using a Wolf 2.7 mm needle arthroscope, biopsies were
obtained from inflamed synovial membrane and oxygen partial
pressure was measured under direct visualization as previously
described [23]. For future immunohistochemical analysis synovial
biopsies were embedded in OCT (Tissue Tek, The Netherlands)
and stored at 280uC or paraffin embedded. Serum (n=28) and
matched synovial fluid (n=19) were collected immediately before
arthroscopy and stored at 280uC.
IL-17A Immunohistochemistry
IL-17A immunohistochemistry was performed using 3 mm
paraffin ST sections. The sections were deparaffinised in xylene
and rehydrated in alcohol and deionised water. Antigen retrieval
was performed by heating sections in solution (10mM citrate
buffer, pH 6.0) in a pressure cooker. Slides were washed with
TBS-Triton 3 times and one time with TBS for 5 minutes. Non-
specific binding was blocked using Dako Protein Block (Dako,
Glostrup, Denmark) for 5 minutes. The blocking buffer was then
removed and sections were incubated with a polyclonal anti-IL-
17A antibody (R&D Systems, Wiesbaden-Nordenstadt, Germany).
Control experiments were performed with (i) an isotype control;
and (ii) an anti-IL-17A antibody block using recombinant IL-17A
(R&D Systems). After incubation overnight at 4uC and washing,
the sections were incubated with biotinylated rabbit anti-goat IgG
antibody diluted in Dako Real Antibody Diluent (Dako) for 30
minutes at room temperature, followed by strepavidin-peroxidase
complex (Dako, Glostrup, Denmark) for 30 minutes at room
temperature. Following washing the slides were visualised by
reacting for 10–15 minutes with Fast Red Substrate-Chromagen
System (Dako). Nuclear counterstaining was performed using
Mayer’s haematoxylin; the sections were then dehydrated, and
mounted in glycerol gelatine. For the quantification of IL-17A
expressing cells in the RA and PsA synovium, 10 high power fields
(HPFs) of one section were analysed per patient and the absolute
number was divided by 10 to obtain the average number of those
cells per HPF. Cell specific markers for CD68 and CD3 cells were
previously quantified in this cohort [23]. In brief sections were
incubated with primary antibodies against mouse-monoclonal
anti-CD68, anti-CD3, (DAKO, Glostrup, Denmark) at room
temperature for 1 hour. A routine three-stage immunoperoxidase
labelling technique incorporating avidin-biotin-immunoperoxi-
dase complex (DAKO, Glostrup, Denmark) was used. Colour
was developed in solution containing diaminobenzadine-tetrahy-
drochloride, counterstained with haematoxylin and mounted.
Slides were analysed using a well established semi-quantitative
scoring method ranging from 0–4 (0= no staining, 1=,25%,
2=25–50%, 3=50–75%, 4=.75% staining)[23] .
IL-17A Co-localisation to Synovial cells
Immunohistochemistry of paraffin embedded ST was per-
formed to detect tryptase+ mast cells with a monoclonal anti-
human antibody (clone AA-1) and CD15+neutrophils with an
anti-CD15 antibody (clone MMA, Acris, Herfordt, Germany).
Dual immunofluorescent staining was performed to identify IL-
17A expressing cells using a polyclonal anti-IL-17A antibody.
Sections were prepared as above then incubated overnight with
primary antibodies to (1) goat polyclonal anti-IL-17/rabbit poly-
clonal Myeloperoxidase (Thermo/Lab Vision), (2) goat polyclonal
anti-IL-17/mouse monoclonal anti-Mast cell-Tryptase (DAKO,
UK) and (3) goat polyclonal anti-IL-17/mouse monoclonal CD4.
Sections were then washed and incubated with secondary
antibodies against, Donkey anti-rabbit AlexaFluor 488 (invitrogen)
or donkey anti-mouse Alexa Fluor 488 (Invitrogen) and Donkey
anti-goat Nothern Light 577 (RnDsystems, UK). Slides were
counterstained with Dapi nuclear stain and mounted with antifade
fluorescent mounting media. The scoring was initially performed
by microscope analysis at high power and then dual immuno-
flourescent staining was performed for validation. IL-17A, CD4,
CD15 and MPO quantification was assessed in ten random high-
powered fields (HPF) of one section per patient. Specificity of the
IL-17A antibody was further tested by pre-incubation of this
antibodywithrecombinanthumanIL-17Ainblockingexperiments,
as well as by obtaining the expected pattern of IL-17, CD4, CD15
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node. All the immunofluor- doublestains were performed in the
positive control tissues. Furthermore isotype-matched control anti-
bodies for IL-17, CD4, CD15 and MPO, were performed as
negative controls.
Cytokine measurement by Multiplex Assay
The MSD multiplex assay was used to quantify IL-17A in
synovial fluids and culture supernatants. IL-6 in synovial fluids and
culture supernatants was quantified by MSD multiplex or ELISA
(R&D systems, Cambridge, UK). The samples and standards were
prepared on multiplex assay plates or ELISA plates in accordance
with the manufacturer’s instructions. The Sector Imager 2400
instrument and software were used to read the multiplex plate, and
absorbance was measured at 450nm in a microtiter plate spectro-
photometer (Dynatech MR4000, Alexandria, VA) for ELISA.
Isolation of peripheral blood mononuclear cells (PBMCs)
and Neutrophils. Peripheral blood mononuclear cells (PBMCs)
from healthy donors were isolated by Ficoll-Metrizoate density
gradient centrifugation (Lymphoprep; Nycomed, UK). Human
neutrophils were purified from healthy donors by dextran sedimen-
tation and Ficollgradient centrifugation followed by hypotonic lysisof
contaminating erthryocytes. Neutrophils were resuspended in 1%
EGM medium prior to experiments. Cells were seeded in 98-well
plates, at a cell density of approximately 500,000 cells/ml in full
RPMI 1640 medium, and cultured under 3% hypoxic or normoxic
conditions for 24hrs. Supernatants were harvested and IL-17 and IL-
6 were quantified by MSD assays and ELISA.
Statistical Analysis
SPSS12 system for windows was used for statistical analysis. Non-
parametric Wilcoxon Signed Rank test, Mann-Whitney U test and
Spearman correlation coefficient were used for analysis of non-
parametric data. p,0.05 was determined as statistically significant.
Results
Localized production of IL-17A within the inflammatory
joint
Serum and SF samples (n=22) were analyzed by IL-17A MSD
assay. Serum IL-17 levels were [1.5pg/ml (0.8–2.8)]. When we
compared matched serum and SF levels, we demonstrated that SF
IL-17A levels [6.9pg/ml (0.9–156)] were significantly higher than
serum IL-17A levels [1.5pg/ml (0.8–2.8)] (p,0.001) (Figure 1A).
Immunohistochemical analysis of IL-17A in ST sections detects
IL-17A positive cells in the sublining layer of all patients; no lining
Figure 1. IL-17A expression is localized to the inflamed joint. IL-17A protein levels were measured by MSD Assay in paired serum/synovial
fluid samples (n=20) (A). Synovial fluid levels were significantly higher than serum levels. Values expressed as median 6 range, *p,0.01, significance
level. Immunohistochemistry was performed in synovial tissue sections from patients with inflammatory arthritis (n=19). (B).The number of
mononuclear cells (white bars) staining for IL-17A was higher than the number of IL-17A positive polymorphonuclear cells (grey bars). Results are
expressed as the number of IL-17A positive cells per high powered field (HPF). (C) Representative images of IL-17A expression in RA (i) vs. PsA (ii) and
mononuclear IL-17A expression (iii) and polymorphonuclear IL-17A expression (iv).
doi:10.1371/journal.pone.0024048.g001
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immunostaining was observed in both mononuclear and poly-
morphonuclear (PMN) cells (Figure 1C). The number of IL-17A
positive cells in each patient were quantified (Figure 1B). The
number of IL-17A positive mononuclear cells tended to be higher
compared to PMN cells [2.9 cells/HPF (0.7–11.4) vs. 0.8cells/
HPF (0–18.10)]. IL-17A positive cells were then categorized by
patient diagnosis – RA or PsA .RA patients (n=11) had more IL-
17A positive mononuclear than PMN cells [2.7cells/HPF (0.7–
11.4) vs. 1.3 cells/HPF (0–7.2)]. A similar trend was also observed
for PsA patients (n=8) [2.9 cells/HPF (0.7–6.30) vs. 0.7 cells/HPF
(0–18.1)]. Furthermore no significant differences were observed in
IL-17A positive cell numbers between RA and PsA cohorts.
Representative images of IL-17A positive cells in RA (i) vs. PsA (ii)
and high power images of IL-17A on MNCs (iii) and PMN (iv) are
shown in Figure 1C.
Production of IL-17A by the innate immune cells – mast
cells and neutrophils
Dual-immunofluorescence staining was performed to identify
the precise phenotype of the IL-17A positive PMN cells identified
within the inflamed synovium. Using dual immunofluorescence
staining we demonstrate IL-17A positive cells co-localised with
tryptase identifying IL-17A positive mast cells (Figure 2A) and
CD15 neutrophils (Figure 2B). Consistent with previous work we
also show IL-17A positive cells co-localised with CD4+ T cells
(Figure 2C). Table 1 shows the % IL-17A positivity on the
different cell types. Percentage was quantified by (i) % double
staining positivity of whole IL-17A cell count or (ii) % double
staining of tryptase +, CD15+ or CD4+ cells. Table 1 shows that
using both quantifications, IL-17A+ expression was highest on
neutrophils, mast cells and CD4 T cells respectively.
Intra-articular pO2 levels and IL-17A production
Synovial tissue pO2 was quantified using a Licox probe and
demonstrated profound levels of hypoxia within the joint as
recently described [22,23,28,29]. When patients were grouped
into those with low pO2 (,20mmHg) or those with high pO2
(.20mmHg) as previously described (23), higher levels of IL-
17A positive mononuclear and PMN cells were associated with
lower tpO2, no difference was observed in SF levels of IL-17A
(Figure 3A,B). Patients with tpO2 ,20mmHg had significantly
more IL-17A positive mononuclear cells than those with
tpO2.20mmHg [3.9 cells/HPF (0.7–6.3) vs. 1.7 cells/HPF (0.7–
11.4)] (p,0.05) (Figure 3B). Patients with tpO2 ,20mmHg also had
a higher numberof IL-17A positive PMN cells than those with tpO2
levels .20mmHg [1.3 cells/HPF (0–18.1) vs. 0.15 cells/HPF (0–
5.10), however this did not reach significance. IL-17A positive
Figure 2. Localisation of IL-17A to neutrophils and mast cells within the inflamed synovium. Representative images of RA synovial tissue
section stained with antibodies against tryptase, CD15 and IL-17A. Merged images indicating co-localisation – yellow.
doi:10.1371/journal.pone.0024048.g002
Table 1. Results are expressed as mean (standard deviation) percentage.
Percentage of cell subtypes expressing
IL-17+/ total IL-17+ cells
Percentage of IL-17+ expressing
cells/ cell subtype
Tryptase+/analysis (n=10) 27.36 (29.09) 78.91 (12)
CD15+/analysis (n=10) 81.08 (29.8) 78.91(29.9)
CD4+/analysis (n=10) 1.28 (4.86) 1.65 (2.54)
doi:10.1371/journal.pone.0024048.t001
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PMN cells in patients with tpO2 levels .20mmHg (p,0.05)
(Figure 3C). When PMNs were examined separately for CD15+IL-
17A+ and Tryptase+IL-17A+ cells, higher levels of CD15+IL-17A+
were demonstrated in patients with tpO2 ,20mmHg, however no
significant difference was observed for mast cells.
IL-17A and IL-6 expression and inflammatory infiltrate
The relationship of IL-17A expression within the inflammatory
joint with markers of inflammation and cellular infiltrate was
assessed. Levels of IL-17A correlated with SF IL-6 levels
(r=0.675, p,0.01). SF IL-17A levels also correlate with the
CD3+ T cell infiltration in the ST lining layer (r=0.545, p,0.05).
The relationship between IL-17A positive cells and inflammatory
cellular infiltrate was also assessed. Neither cell type correlated
with CD3+ T cell expression however the expression of IL-17A
PMN cells correlated with the sublining expression of CD68+
macrophages (r=0.618, p,0.01).
The effect of hypoxia on IL-17A production in PBMC and
neutrophil cultures.
IL-17A was measured in mononuclear cell and neutrophils
following exposure to 3% hypoxia. No significant difference in
IL-17A levels under normoxic or hypoxic conditions was observed
(Figure 4 A, C). In contrast IL-6 levels were significantly induced
in mononuclear cells (Figure 4B) (p,0.05) with no significant
difference observed in neutrophils (Figure 4D).
Discussion
In this study we demonstrate in vivo the presence of IL-17A
expressing -neutrophils, mast cells and T–cells within the inflamed
synovium. Percentage positivity of IL-17A was highest on neutro-
phils, followed by mast cells and then CD4+T cells. We demonstrate
thatIL-17Aishighlyexpressedintheinflamed jointand isassociated
with the expression of IL-6 and inflammatory cell infiltrate.
Furthermore, we demonstrate tissue mononuclear cell expression
of IL-17A is significantly higher in patients with low in vivo tissue pO2
levels. Finally no difference in IL-17A levels was observed following
exposure to hypoxia in vitro.E x p r e s s i o no fI L - 1 7 Ao nC D 1 5 +neu-
trophils and tryptase+ mast cells in addition to CD4+T-cells further
supports the concept that IL-17A plays a key roleinthe pathogenesis
of inflammatory arthritis. This association with hypoxia, is most
likely an indirect effect due to induced infiltration of inflammatory
immune cells into the synovial pannus [22,28].
IL-17A expression is significantly higher in inflammatory
arthritis SF compared to serum levels, suggesting IL-17A
Figure 3. Increased systemic expression of IL-17A at low pO2. (A) Patient synovial fluid samples (n=22) were assessed by MSD assay for the
expression of IL-17A. Cytokine levels were then grouped according to patient tpO2 levels or .20mmHg. No significant difference in synovial fluid levels
was observed between the two groups. (B) Synovial tissue pO2 levels (n=18) were also examined in relation to the expression of IL-17A positive
mononuclear (white bars) and polymorphonuclear cells (grey bars). Patients with tpO2 levels ,20mmHg (n=9) had significantly more IL-17A positive
mononuclear cells than those with tpO2 levels .20mmHg (n=9) (p,0.05). Patients with tpO2 levels ,20mmHg (n=9) also had a higher number of IL-
17A positive polymorphonuclear cells than those with tpO2 levels .20mmHg (n=9). This difference was not statistically different.
(C) Representative images of IL-17A expression on mononuclear cells from a patient with high tpO2 levels vs a patient with low tpO2 levels are shown.
doi:10.1371/journal.pone.0024048.g003
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with our previous findings [13]. Furthermore, IL-17A expression
within the joint has been shown to strongly correlate with disease
activity and inflammation [13,30]. Immunohistochemical analysis
of ST from inflammatory arthritis patients demonstrated sublining
expression of IL-17A, particularly in areas of lymphoid infiltration.
In previous reports these cells were mainly mononuclear [16]
although we now demonstrate, IL-17A+ synovial PMN cells co-
localizing IL-17A with tryptase+ mast cells and CD15+ neutro-
phils. Murine mast cells and neutrophils have been previously
shown to express IL-17A following specific stimulation; however, it
has not been well established in human tissue [30,31]. Further-
more, these cells have are known to be a key source of proin-
flammatory cytokines in human RA ST [31], and interact with RA
synovial fibroblast cells via the production of soluble mediators to
enhance IL-6 secretion [32]. Here we demonstrate mast cells and
neutrophils expressing IL-17A within the inflamed synovium. Both
cell types have been implicated in the pathogenesis of CIA and
other models of experimental arthritis [33,34,35].
Our data supports Hueber et al [20], who demonstrated the
majority of IL-17A expressing cells in RA synovial tissue were co-
localised to mast cell [20]. Furthermore they showed that pro-
inflammatory stimuli such as TNFa,C5 and LPS alone and in
combination induce RORC-dependant IL-17A production from
mast cells in vitro. This data suggests that mast cells are a major
source of IL-17A in the inflamed synovium, which can be induced
by the pro-inflammatory microenvironment of the joint. In our
study we showed that IL-17A expression was localized to tryptase+
mast cells, CD15+ neutrophils and CD4+T cells, with highest
expression observed on CD15+ neutrophils. The expression of IL-
17A on several cell subtypes within the synovium, suggest it plays
an important immune-modulatory role. Our data is consistent
with recent reports in psoriasis skin biopsies showing similar IL-
17A expression patterns [36,37].
Furthermore, IL-17A
+ PMN cells correlated with sublining
CD68 expression which again supports previous studies that
demonstrate mast cells can activate resident synovial macrophages
via the production of various proinflammatory mediators and
recruit both neutrophils and monocytes into the joint. Mast cells
and neutrophils have both been implicated in the initiation and
progression of arthritis [10,38]. IL-17A is a well established
mediator of angiogenesis and inflammatory cell influx via the
production of cytokines and chemokines [39,40,41]. The expres-
sion of IL-17A by these cells further implicates the pivotal role IL-
17A plays in the pathogenesis of RA.
In addition we demonstrated that in vivo measures of hypoxia
were associated with synovial mononuclear IL-17A expression.
This is supported by previous studies demonstrating the effect of
Figure 4. The effect of 3% hypoxia on IL-17A and IL-6 in vitro. Peripheral blood mononuclear cells (n=12) and neutrophils (n=6) were
cultured for 24hrs under 3% hypoxic conditions and normoxia. Hypoxia had no effect on IL-17A expression (A), but significantly induced IL-6
expression in mononuclear cells (B). Hypoxia had no effect on IL-17A(C) or IL-6 (D) in neutrophils. Data expressed as the mean 6 SEM. P,0.05
significantly different from normoxic conditions.
doi:10.1371/journal.pone.0024048.g004
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tissue have shown T cell accumulation in hypoxic tissue [42,43],
and its expression has been previously shown to be associated with
hypoxia. Exposure of murine CD3+ T cells to hypoxia enhances T
cell expression, proliferation and activation in a HIF-1a dependent
manner. We have previously shown that low hypoxia is inversely
associated with synovial mononuclear cell infiltrates [23], vascu-
larity [22] and others have shown that HIF1a is co-localised to
synovial mononuclear cells in the joint [44], and with potent
chemotactic factors macrophage inflammatory protein CCL20
(MIP3a) and Stromal cell derived factor-1 (SDF-1) and angiogen-
esis [45]. Hypoxia enhances amyloid beta peptide induced IL-17A
production and TH-17 differentiation in PBMC cultures [46].
Normally neutrophils have a short half-life and rapidly undergo
apoptosis; however following exposure to hypoxia neutrophil
apoptosis can be suppressed [47,48,49].
While we found no increase in the number of IL-17A+ mast
cells in patients with low tpO2 levels, previous studies suggest mast
cells respond early to hypoxic insult in rat models of cerebral
ischemia [50,51]. Exposure to hypoxia has increased production of
MMPs and tryptase by mast cells leading to tissue degradation
[52]. The expression of IL-17A and its receptor are upregulated in
both murine and human ischemic tissue compared to non ischemic
tissue [53]. Murine mast cells have been shown to produce IL-17A
in response to stimulation with TLR2 ligands [54]. Furthermore,
human mast cells have been shown to stimulate activated T cells
suggesting a potential role in TH-17 differentiation. Mast cells have
been shown to be early responders to a hypoxic insult and
degranulation of mast cells can be detected histologically 1–2 hours
after the initiation of arthritis in the K/BxN model [8,50,51,52].
In this study while IL-17A expression was associated with low
pO2 levels and hypoxia induced IL-6 expression in vitro, no effect
on IL-17A expression in vitro was observed. This suggests that the
association between hypoxia and IL-17 is indirect and possibly due
to the effect of hypoxia on several pro-inflammatory pathways and
influx of inflammatory immune cells into inflamed joint. Hypoxia
did induce IL-6 levels in monocyte, suggesting that hypoxia
induces differential cytokine signaling pathways which may
depend on cell-type. This is consistent with our previous work in
which we demonstrated that patients with low in vivo measures of
tpO2 were significantly associated with high CD3+T cells and
CD68 macrophages infiltrates and increased expression of TNFa,
IL-1b, IFN-c and MIP-3a [23]. The effect of hypoxia on pro-
inflammatory mediators has been demonstrated by several in vitro
studies [55,56,57] showing induction of TNFa, IL-1b, VEGF.
Induction of macrophage inflammatory protein CCL20 (MIP-3a)
in SF monocytes and ICAM in lymphocytes following exposure to
hypoxia has also been demonstrated [23,50,58]. Whether hypoxia
is driving the increase of IL-17A expression in the joint or whether
it is due to increased inflammation is unclear. The association of
hypoxia with inflammatory cells and MIP-3a induction would
support a role for a hypoxia-induced influx of inflammatory
immune cells as MIP-3a is involved in attracting IL-17A positive
cells to the joint. However, several studies have suggested that TH-
17 cells do not acquire a fully activated phenotype until they are
resident within the inflammatory joint [59,60] where the presence
of soluble mediators and cell-cell interactions influence their
differentiation [18,61,62,63].
In conclusion we have localised IL-17A expression to neutro-
phils and mast cells in inflamed human synovium, with highest
positivity demonstrated on neutrophils. The expression of IL-17A
in the serum, SF and tissue of inflammatory arthritis patients was
associated with inflammation and cellular infiltrate. While no
direct relationship between hypoxia and IL-17A production was
established, hypoxia may influence IL-17A expression by upregu-
lating production of various soluble mediators [23], in addition to
induction of leukocyte influx into the synovium inflammatory
processes.
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